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Background: Image-guided laser ablation therapy (LAT) of benign thyroid nodules demonstrated
favorable results in randomized trialswith fixedmodalities of treatment. The aimof this retrospective
multicenter study was to assess the effectiveness, tolerability, and complications of LAT in a large
consecutive series of patients from centers using this technique in their routine clinical activity.
Patients: Clinical records of 1534 consecutive laser-treated nodules in 1531 patients fromeight Italian
thyroid referral centers were assessed. Inclusion criteria were as follows: solid or mixed nodules with
fluid component up to 40%; benign cytological findings; and normal thyroid function.
Methods: LAT was performed with a fixed-power protocol, whereas the number of applicators and
illumination times were different according to target size. From one to three illuminations with pull-
back technique andwith a total energy delivery based on the nodule volumewere performed during
the same session. PatientswereevaluatedduringLAT,within30days, and12monthsafter theprocedure.
Results: Total number of treatments was 1837; 1280 (83%) of nodules had a single LAT session.
Meannodule volumedecreased from2724mLat baseline to 88mL12months after treatment
(P  .001). Mean nodule volume reduction was 72%  11% (range 48%–96%). This figure was
significantly greater in mixed nodules (79%  7%; range 70%–92%) because they were drained
immediately before laser illumination. Symptoms improved from 49% to 10% of cases (P  .001)
andevidenceof cosmetic signs from86%to8%of cases (P .001). Seventeen complications (0.9%)
were registered. Eight patients (0.5%) experienced transitory voice changes that completely re-
solvedat theear-nose-throatexaminationwithin2–84days.Nineminor complications (0.5%)were
reported. No changes in thyroid function or autoimmunity were observed.
Conclusions: Real practice confirmed LAT as a clinically effective, reproducible, and rapid outpa-
tient procedure. Treatments were well tolerated and risk of major complications was very low.
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Image-guided tissue ablationwith both thermal and non-thermal sources (1) has been used with favorable re-
sults in percutaneous treatment of benign thyroid nodules
(BTNs) (2–4). Ultrasound-guided (US-g) ablationwith la-
ser was the first procedure to be proposed for these ap-
plications (5) and, since the initial feasibility studies (6–8),
both noncontrolled andprospective randomized trials (9–
20) have confirmed the clinical effectiveness and safety of
this technique. Due to its moderate cost and its efficacy as
an outpatient procedure, laser ablation therapy (LAT) is
now increasingly used in thyroid referral centers.
The currently available data come mostly from limited
series of patients in prospective clinical trials, character-
ized by strict enrollment criteria and standard modalities
of treatment (15–17, 19, 20) and do not provide a clear
definition of the actual effectiveness and risk of compli-
cations of LAT in real practice. In fact, clinical outcomes
and type and incidence of adverse effects are strongly in-
fluenced by variables such as structural (solid, mixed, or
cystic) characteristics of nodules, size and location of the
target lesion and local expertise and treatment algorithm
(12, 13, 19, 20).
The aim of this retrospective multicenter study was to
assess the effectiveness, tolerability, and type and rate of
complications of LAT for benign thyroid nodules in the
current clinical practiceof eight centersoperatingwith this
technique in Italy.
Materials and Methods
After a consensus meeting, a multidisciplinary board of endo-
crinologists, interventional radiologists, and surgeons developed
and approved a database for the retrospective assessment of the
efficacy, tolerability, and risk of complications of LAT in the
treatment of benign thyroid nodules.
This multidisciplinary team, under the supervision of an ex-
ternal monitor, reviewed the clinical records of more than 2500
patients from those centers that have adopted this technique
during the last 10 years. Based on the recommendations of the
multidisciplinary team, the individual centers have ruled out
from the study all the patients with the following characteristics:
1) incompleteness of data concerning the cosmetic appearance or
the tolerability, side effects, and complications of the procedure;
2) dropout at follow-up; 3) patients not eligible for the study
because of abnormal baseline thyroid function or concomitant
treatment modalities; 4) treatments performed during the initial
period of the learning curve of laser technique; and 5) use of
treatment algorithms with variable or uncertain output energy
power or illumination time. After a careful assessment of the
entire population, treatment modalities, characteristics of the
nodules, volume reduction after LAT, and frequency, type, and
management of complications, 1531 patients were registered.
Patients
Eight Italian thyroid referral centers with specific expertise in
minimally invasive treatment of thyroid lesions participated in
the study. LAT was performed in all these centers with the same
commercially available ultrasound system equipment (EchoLa-
ser; Elesta) andwith a similar treatment and follow-up protocol.
In five centers, procedures were performed by endocrinologists,
in two by interventional radiologists, and in one by surgeons. All
institutes had at least 2 years’ experience in LAT and performed
more than 20 thyroid thermal ablation procedures per year. Pa-
tients enrolled in the previously published Italian Multicenter
Study (21) or in other randomized controlled trials were not
included in the present series.
The study was conducted in compliance with the Helsinki
Declaration and the local bioethics committees. Informed con-
sent for each procedurewas obtained fromall patients; informed
consent was waived for this retrospective investigation. The re-
search was approved by the institutional review board of each
participating center.
Inclusion criteria forLATwere thepresenceofpressure symp-
toms or cosmetic concerns due to thyroid nodules, repeat benign
cytological findings, normal serum TSH and free T4 (FT4) val-
ues, and hypoactive cold appearance at radionuclide thyroid
scan in patients with low-normal serum TSH level. At variance
with the Italian Multicenter Study, performed on solid nodules
only (21), the present series included nodules of variable volume
and structure, and, specifically, mixed lesions with a fluid com-
ponent up to 40% .
Five treatment variableswere present: number of applicators,
number of illuminations and total energy delivery, modality of
local anesthesia, conscious sedation regimen, and analgesic
treatment during and immediately after the treatment session.
Routine coagulation tests were performed before the proce-
dure and included prothrombin time, partial tromboplastin
time, and platelet count. A general consensus among centers was
followed on the basis of the guidelines used for interventional
procedures in other organs, such as liver, kidney, or lung (22).
Technique
Treatment procedures followed those previously applied and
published elsewhere (8). Briefly, the number of introducer nee-
dles and of optic fibers (from two to four applicators) to be
inserted was based on nodule size. Under US-g, the introducer
needles were inserted into the target thyroid nodule along its
longest axis.
Each treatment was performed with a fixed-power protocol
(3W), but the illumination time was different case by case ac-
cording to target size, shape, and structure. Each illumination
time ranged from a minimum of 400 seconds to a maximum of
600 seconds to maintain the total energy applied between 1200
and 1800 J per fiber. Depending on the size of the nodule, one to
three consecutive illuminations with a pullback technique were
performed during the same treatment session. In mixed lesions
with a relevant fluid part, the drainage of the fluid component
was performed immediately before laser illumination according
to the described technique (20).
Follow-up
Patient follow-up was performed on the basis of previous
recommendations (8, 9, 17, 19). Patients were evaluated during
and immediately after the LAT session, within 24 hours, during
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periprocedural session (within 30 d), and 12 months after the
procedure. In the event of complications, the related imaging
examinationswereperformed immediately after symptomonset.
Local pressure symptoms and clinical assessment of cosmetic
signs were evaluated according to previously published criteria
(23) and according to the criteria set out by themultidisciplinary
team. Briefly, local symptoms were evaluated by means of a
questionnaire assessing the presence/absence of one the follow-
ing symptoms: 1) no symptoms; 2) mild pressure complaint; or
3) neck constriction and/or swallowing difficulty. The clinical
assessment of the signs of nodular goiterwasperformedbyvisual
inspection of the following: 1) nodule not visible; 2) nodule vis-
ible only with hyperextended neck; or 3) nodule visible at a dis-
tance greater than 1 m. The use of analgesics or other drugs and
the duration of treatment were recorded. All patients who
showed minor voice changes were evaluated by an ear-nose-
throat specialist with fiber optic laryngoscopy.
Questionnaire
The questionnaire administered by each center included the
following: modality of local anesthesia, conscious sedation
and/or analgesia regimen; number and size of nodules; number
of treatment sessions; nodule volume and serum TSH, FT4, and
thyroperoxidase antibodies at baseline and 12 months after
LAT; number and types of major or minor complications and
side effects; and management of complications, time of their
detection and period, or treatment required for their recovery.
The definition of complications was consistent with the stan-
dardized terminology and reporting criteria for image-guided
tumor ablation proposed by other authors (22) and with the
classification criteria suggested by the Society of Interventional
Radiology (24). A major complication was an event that, if left
untreated, could be life threatening, could result in minor or
prolonged hospital stay, or could lead to permanent adverse se-
quelae with substantial morbidity and disability. All other com-
plications were considered minor.
Side effects were considered common untoward and unde-
sired consequences that did not require an increase in level of
care. A numeric scale (visual rating scale) was used to rate pain
intensity (0, no pain, to 10, severe pain) (25). Accordingly, the
pain was categorized as mild (4 of 10), moderate (5 of 10 to 6
of 10), or severe (7 of 10). Pain lasting less than 3 days was
judged as acute.
The nodule populations were classified by the multidisci-
plinary team, in agreement with the data available in the litera-
ture (12, 26, 27), into three classes according to baseline volume:
nodules with initial volume of 13 mL or less were classified as
small, those between 13.1 and 30.0 mL as medium, and those
greater than 30 mL as large. Two physicians (C.M.P. and E.P.)
with substantial experience in the management of patients un-
dergoing LAT prepared the questionnaire and contacted the
centers.
Statistical analysis
Statistical analysis was performed by using the Statistical
Package for Social Science (SPSS), release 15.0. Continuous vari-
ables were expressed as mean  SD and categorical variables
displayedas frequencies andcomparedusing the2orFisher test,
as appropriate. A value of P  .05 was considered statistically
significant.
Results
Clinical records from January 2004 to December 2013
were reviewed. The study included 1534 benign thyroid
nodules in 1531 patients (444 male/1087 female patients;
mean age 54.1 y) who were ablated percutaneously
through LAT. The number of nodules treated at each cen-
ter ranged from 36 to 341.
The mean volume of the treated nodules was 27  24
mL (range 1.4–216 mL). The total number of treatment
sessionswas 1837.One thousand two hundred and eighty
of 1534 nodules (83%) were treated with a single LAT
session, 205 (13%) with two sessions, and 49 (3%) with
three sessions (mean 1.2, range 1–3; Table 1). The total
energy delivery in the different nodules ranged from 1200
to 1800 J using a single applicator and a single illumina-
tion to 14 400–21 600 J with four applicators and three
illuminations. The drainage of the liquid component,
when present, was performed immediately before thermal
treatment. All nodules were benign at cytological
assessment.
Effectiveness
Mean nodule volume in solid and mixed nodules de-
creased from 27  24 mL at baseline to 8  8 mL 12
months after treatment (P  .001). LAT induced a mean
nodule volume reduction at 12 months that ranged from
48% to 96% (mean 72% 11%) vs baseline. In the sub-
groupofnoduleswith a fluid componentup to40%(mean
30% 6%), mean volume decreased from 12 18mL at
baseline to 2.4 2.3 mL 12 months after treatment (P
.001),with amean volume reductionof 79%7%(range
70%–92%). The volume reduction in small, medium, and
large nodules was 73% 10%, 73% 11%, and 71%
10%, respectively.
Serum TSH and FT4 levels did not change significantly
at the 12-month check-up vs the baseline values (1.7 0.7
vs 1.6 0.7, P . 394 and 11.7 1.4 vs 11.8 1.8, P
. 674, respectively).
Local symptoms score improved from 49% to 10% of
cases (P  .001) and evidence of cosmetic signs changed
from 86% to 8% of cases (P  .001). In more detail, the
local symptoms score improved from 15% to 3% in small
nodules (P .001), from42% to 11% inmediumnodules
(P  .001), and from 90% to 19% in large nodules (P 
.001). Evidence of cosmetic score improved from 80% to
5% in small nodules (P  .001), from 86% to 8% in
medium nodules (P  .001), and from 93% to 14% in
large nodules (P  .001).
Complications rate
Seventeen complications (0.9%of thewhole number of
LAT sessions) were recorded, including 8 major (0.5%)
doi: 10.1210/jc.2015-1964 press.endocrine.org/journal/jcem 3905
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/100/10/3903/2835815 by BIBLIO
TEC
A FAC
O
LTA' D
I SC
IEN
ZE PO
LITIC
H
E user on 28 M
ay 2020
and 9 minor (0.5%) complications (Table 2). No patient
had life-threatening complications (24) or required over-
night admission, intensive care, or surgical repair. A
statistically significant difference was detected among
the centers (P  .003, P  .011, and P  .001, respec-
tively). The rate of major complications was lower in
patients treatedwithout local anesthesia orwith no con-
scious sedation than in those managed with local anes-
thesia and conscious sedation (0.15% vs 0.81%, P 
.086, and 0.22% vs 0.98%, P  .066, respectively).
Conversely, complaints of side effects were more fre-
quent in subjects treated without local anesthesia
(2.08% vs 0.93%, P .082, and 41% vs 22% P .001,
respectively).
Table 1. Demographic Data, Effectiveness, Incidence of Major and Minor Complications, and Side Effects in Eight
Participating Centers
Hospital
Patients,
n, Males/
Females Age, ya
BTNs,
n
Volume
of BTNsa
Sessions,
mean
VR at
12th mo
Patients
Treated
With Two
or More
BTNs, n
Local
Anesthesia
Sedation,
Yes/No
Major
Complications,
n, %b
Minor
Complications,
n %b
Side
Effects,
n, %c
Albano
Laziale
341,
110/231
51.5  13.7 341 13  12
(2–126)
1,5 6.7  10 Yes No 1 (0.3) 1 (0.3) 37 (10.9)
Atri 138,
22/116
52.1  12.1 138 13  9
(1.5–45)
1 7.6  8 Yes Yes 3 (2.2) 2 (1.4) 20 (14.5)
Alzano
Lombardo
36,
4/32
58.6  15.0 36 5  3
(2–21)
1 8.4  5 Yes Yes 0 (0.0) 0 (0.0) 1 (2.8)
Bari 45,
10/35
52.0  13.3 45 24  19
(1.4–93)
1 9.2  13 Yes Yes 1 (2.2) 0 (0.0) 13 (28.9)
Cosenza 242,
62/180
54.4  11.8 242 19  13
(1.9–84)
1 7.6  8 Yes No 0 (0.0) 0 (0.0) 54 (22.3)
Livorno 334,
111/223
51.6  31.1 337 49  18
(10–78)
1.4 6.8  8 3 No No 1 (0.3) 0 (0.0) 184 (54.6)
Perugia 58,
26/32
58.1  8.9 58 25  29
(7–215)
1.1 7.6  7 Yes Yes 2 (3.4) 2 (3.4) 51 (87.9)
Perugia 189,
81/108
56.1  9.9 189 20  24
(3–216)
1.1 7.3  11 No Yes 0 (0.0) 4 (2.1) 71 (37.6)
Pisa 148,
18/130
52.6  13.0 148 47  27
(6–172)
1.1 7.2  11 No Yes 0 (0.0) 0 (0.0) 32 (21.6)
Combined
Hospitals
1531,
444/1087
54.1  14.3 1534 27  24
(1.4–216)
1.2 7.2  11 3 8 (0.5) 9 (0.6) 463 (30.2)
a Mean  SD.
b Value calculated per LAT sessions.
c The values include all side effects intraoperatively and within 24 hours days after the procedure.
Table 2. Complications and Side Effects in 1531 Patients Who Underwent LA of Thyroid Nodules
Complications and Side Effects, n, %b
Time of Detection
Type of
Complications
(SIR Class)a Intraoperatively
Immediately
Postoperatively
(Within 24 h)
Periprocedural
(Within 30 d)
Delayed
(After 30 d)
Time to
Recovery, d
Major
Voice change (C) 8 (0.5)c 2–84
Minor
Hematoma (B) 8 (0.4) 2–10
Skin burn (B) 1 (0.1) 10
Side effects
Pain (A)
Mild 194 (10.6) 61 (3.3) 1
Moderate 30 (1.6) 34 (1.9) 1–2
Severe 4 (0.2) 2–3
Vasovagal reaction (A) 12 (0.7)
Cough (A) 1 (0.1)
Fever (37.5ºC-38.5ºC) (A) 141 (7.7) 1–4
Abbreviation: SIR, Society of Interventional Radiology.
a SIR guideline criteria (24).
b Value calculated per LAT sessions.
c Detected in nodules with large volume greater than 30 mL.
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Major complications
Eight patients (0.5%) experienced voice changes oc-
curring immediately after the procedure, and fiberoptic
laryngoscopy confirmed an ipsilateral vocal cord palsy. In
six of these cases (75%), thyroid nodules were close to the
inferomedial portion of thyroid, whereas in two cases
(25%), the target lesions were near the lateral margin of
the gland. All patients recovered their voice completely
within 2–84 days (mean 22 d) after oral administration of
corticosteroids for a time ranging from 2 days to 2 weeks
(Table 2). Fiberoptic laryngoscopy was performed after 3
months in all these cases and demonstrated recovery of
normal function of the vocal cords.
Minor complications and side effects
Nine minor complications (0.5%) were reported, in-
cluding subcapsular or perithyroidal hematoma and skin
burn in eight and one patients, respectively (Table 2). He-
matomaswere small (5mL) anddisappearedwithin 1–6
hoursafter a30-minute compression.Theonly caseof skin
burn occurred accidentally in a single center in the early
phase of the learning curve (Figure 1). Healing occurred
after 10 days with oral administration of antibiotics.
Allminor side effects (intraoperatively andwithin 24h)
after the maneuver were recorded in 463 of 1837 LA ses-
sions (30.2%) (Table 1). During LTA sessions 194 pa-
tients (10.6%) experienced mild and 30 (1.6%) moderate
burning pain, with sensation of local heat sometimes ra-
diating to the jaw, ipsilateral dental arch, mandibular an-
gle, or shoulder, and, rarely, thoracic backpain.These side
effects lasted a few seconds and disappeared as soon as the
laser was switched off.
There were 12 intraoperative cases of vasovagal reac-
tions (0.7%), with sweating and difficulty in breathing.
Tilting the bed in Trendelemburg position controlled
symptoms within a few minutes. Cough occurred in one
case (0.1%) and disappeared as soon as the laser energy
was turned off.
Mild, moderate, and severe pain were reported in 61
(3.3%), 34 (1.9%), and 4 (0.2%) patients, respectively,
immediately or within 24 hours of the procedure. In all
cases pain was controlled with oral analgesics and disap-
peared within 3 days. One hundred forty-one patients
(7.7%) experienced mild or moderate fever (up to a max-
imum of 38.5°C) lasting up to 3 days that disappeared
with antipyretics (acetaminophen tablet 1000 mg) or
corticosteroids (prednisone tablet 5 mg). No complica-
tions or side effects were observed within 30 days after
the treatment sessions. All the above data are summa-
rized in Table 2.
Discussion
US-g laser thermal ablation is increasingly used in the
treatment of symptomatic or steadily growing thyroid
nodules that are benign at cytological assessment (2–4).
Several randomized controlled trials and a few experts’
reviews state thatLAT is awell-tolerated and substantially
safe procedure (2). Because these data come mostly from
selected series of patients treated with a fixed algorithm,
they may not provide the actual definition of the effec-
tiveness, tolerability, and risk of complications of the pro-
cedure in everyday clinical practice. Thus, the present
study was based on a consecutive series of unselected be-
nign nodules of variable size and structure. Patients were
treated in the participating centers during their usual clin-
ical activity with the same equipment and technique but
with a case-by-case modality of treatment and a total en-
ergy delivery based on the initial volume.
This large retrospective series demonstrates that LAT
induces, mostly with a single treatment, a clinically rele-
vant volume reduction, with a mean nodule decrease that
ranges from 48% to 96% (mean 72% 11%vs baseline)
12 months after treatment. The volume reduction regis-
tered in this study was definitely greater than in previous
prospective randomized trials on LAT of solid cold nod-
ules (6, 15–19). This higher effectiveness was due to sev-
eral factors. In the present series, up to four optical fibers
were used for large volume lesions, and the total energy
deliverywas increased according to the baseline size of the
Figure 1. Neck of a 38-year-old woman at the end of the LAT
session. The picture shows the actual features of the skin burn that
may be induced by LAT. The injury is represented only by a small size
area of erythema in the puncture sites (arrow) of the fine needles used
for laser ablation technique.
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lesion to be ablated.Our results demonstrated that if there
is a direct correlation between the amount of energy de-
livered and the baseline volume of the nodule, a greater
volume reductionmay be attained (27). Inmixed nodules,
moreover, the preliminary drainage of the fluid compo-
nent allowedamarkedvolumedecrease (79%7%)with
results similar to those reported with other techniques
(such as radiofrequency) in noduleswith a large fluid com-
ponent (28–30).
Serum levels of TSH and FT4 did not change signifi-
cantly 12 months after laser treatment. These data con-
firm previous reports from randomized controlled trials
on the risk of thyroid function and autoimmunity
changes (16, 17).
Whereas various and even severe complications of LAT
have been described in previous reports (12, 31, 32), in the
present series, major complications of LAT were rare
(0.5% of cases). Voice changes occurred in nodules of
large volume (30 mL) that were located close to the in-
feromedial portion of the thyroid. Operators should thus
be aware of the risk of injury to the recurrent laryngeal
nerve when treating areas near the presumptive path of
recurrent laryngeal nerve, especially when using multiple
fibers. No damage to the trachea wall or nodule colliqua-
tion, anecdotally reported in previous case reports, was
recorded.Theseunusual complicationswereprobablydue
to incorrect positioningof the laser fiber tip by anoperator
in the initial phase of his learning curve (32) or by delivery
an excessive amount of energy (12). Indeed, liquefactive
changes can occur if more energy than needed to induce
coagulative necrosis is released in the target tissue (12).
The low rate of major complications in the present se-
ries is due to the use of the procedure established since the
early 2000s (8) with multiple heat sources and a pullback
technique. The use of thin (21 G) needles allowed a non-
traumatic positioning of optical fibers into the target and
the accurate monitoring of the treatment (27). The rate of
major complicationswas lower inpatients treatedwithout
local anesthesia; a higher frequency of side effects was
observed in those patients treated with local anesthesia.
These data can be explained by the role pain played during
the treatment. The onset of pain that occurs when heat
reaches the thyroid capsule represents a useful alarm
symptom, inducing the operator to repositioning the fiber
tip at a safety distance (at least 10 mm) from the vital
cervical structures, thus reducing the risk of complica-
tions. The preliminary use of a local anesthetic, on the
contrary, might mask pain, which therefore appears later
when the side effects are already occurring (33).
Minor complications were infrequent as well (0.5%).
Small perithyroidal or subcapsular hematomas were rap-
idly controlledwithout treatment. Skin burnwas rare, and
a single skin burn occurred in a nodule treated with more
than three illuminations (Figure 1). In this case the high
temperature of the proximal portion of the needle caused
a scorchingof the skinwhile itwasbeing removed fromthe
neck. At the end of LAT session, a rapid extraction of the
needle while keeping the output off easily prevents this
minor but unpleasant complication. Rapidly resolving va-
sovagal reactions were probably due to stimulation of ca-
rotid sinus, neck hyperextension, or anxiety. Low-grade
fever sometimes observed in large size nodules was prob-
ably due to the release of mediators of the inflammatory
response after massive ablation-induced cell death.
Noteworthy, these results were obtained without the
specific methods for the protection of critical structures,
such as the liquid-isolating region technique or the swal-
lowing of cold water, that are used with the radiofre-
quency or microwaves ablation (34–37). In particular,
before inserting MW antenna, a mixture of 0.9% lido-
caine and physiological saline may be infused into the ap-
propriate area of the surrounding thyroid capsule to
achieve a liquid-isolating region and to protect the vital
structures of the neck (carotid artery, trachea, esophagus,
and nerves) (36). During the multiple imaginary radiofre-
quency ablation units (38) adjacent to the esophagus, the
patient may be asked to swallow cold water (34); to pre-
vent skin burns at the electrode puncture site, an ice bag
may be applied during the procedure. Finally, because ra-
diofrequency current passes through the heart during thy-
roid radiofrequency ablation, the use of bipolar electrodes
is always suggested to avoid potential complications such
as myocardial infarction and arrhythmia in patients with
cardiac problems (34).
This study was not formally designed to include the
costs of procedures, but the financial advantages of the
management with LAT of symptomatic benign nodules
are clear. The price of a disposable LA device is about 350
USD and includes the rent of the laser generator, and the
team of operators (two physicians and one nurse) is en-
gaged for a total of 30 minutes. The treatment does not
require hospitalization or any routine postprocedural fol-
low-up because the rate of complications is definitely low.
No thyroid function monitoring is needed.
Conclusions
Most benign thyroid nodules are asymptomatic and re-
main nearly stable over time. However, a fair number of
patients of them (especially in borderline iodine deficient
regions) show a slow but progressive growth that, due to
the lack of medical treatments, is the cause of patient con-
cern, repeatmedical consultations, and, frequently, of thy-
roid surgery. A single laser treatment performed with a
nodule-tailored approach in the outpatient clinic on nod-
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ules, which are becoming clinically symptomatic is fol-
lowed in clinical practice by relevant reduction of the nod-
ule volume and by clear improvement of mechanical
symptoms and undesirable cosmetic appearance. Volume
reduction continues over time until 12months after initial
treatment and remains stable for at least a few years with
thyroid function completely maintained (19). Indeed, a
singleLAT induces ahigh rate of volume reduction in solid
nodules, with this figure increasing significantly in mixed
nodules with fluid component up to 40%.Results, even in
large nodules, are comparable with those reported with
other techniques in smaller lesions (26, 38–40).Due to the
use of fine needles, the risk of major complications are
lower than those reported with other thermal treatments
(34, 37).
In light of the data provided by this study and of the
robust evidence of 2 decades of literature, laser thermal
ablation is confirmed as a clinically effective, well-toler-
ated, and safe minimally invasive technology for nonsur-
gical management of symptomatic benign thyroid lesions.
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